Company Logo

777.74 USD

9.98 (1.30%)

Last updated Dec 6, 2:30 PM

Yesterday High

$767.85

Yesterday Low

$753.60

52w High

$1,202.55

52w Low

$737.86

Market Cap.

$84.3B

52w Change

-7.43%

This is a preview of the full version of Prosperse

Trending News

Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease
Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease

Regeneron Pharmaceuticals and Sanofi's drug Dupixent showed successful treatment of patients with chronic spontaneous urticaria and bullous pemphigoid, two inflammatory skin diseases, in Phase 3 trials.

Vandana Singh

Sep 11, 2024

EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile
EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile

Regeneron presented new analyses of EYLEA HD and EYLEA at the EURETINA meeting, highlighting the long-term efficacy, safety, and extended dosing intervals of these treatments for wet age-related macular degeneration and diabetic macular edema.

Regeneron Pharmaceuticals, Inc.

Sep 11, 2024

Prediction: These 2 Companies Will Split Their Stocks by 2027
Prediction: These 2 Companies Will Split Their Stocks by 2027

The article discusses Eli Lilly and Regeneron Pharmaceuticals as potential stock split candidates due to their strong business performance and high share prices. It suggests that these companies could see their share prices continue to rise, making a stock split a likely possibility in the near futu...

Prosper Junior Bakiny

Sep 11, 2024

Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU

A Dupixent (dupilumab) confirmatory phase 3 study met the primary and key secondary endpoints for the treatment of patients with uncontrolled, biologic-naïve chronic spontaneous urticaria (CSU) receiving background therapy with antihistamines. The study showed clinically meaningful reductions in itc...

N/A

Sep 11, 2024

Communiqué de presse : Dupixent : améliorations significatives du prurit et de l’urticaire confirmées par une étude de phase III chez des patients présentant une urticaire chronique spontanée
Communiqué de presse : Dupixent : améliorations significatives du prurit et de l’urticaire confirmées par une étude de phase III chez des patients pré...

Dupixent, a drug developed by Sanofi and Regeneron, has met its primary and key secondary endpoints in a Phase III study for the treatment of chronic spontaneous urticaria (CSU). The study showed Dupixent reduced pruritus and urticaria scores by nearly 50% compared to placebo in patients with inadeq...

N/A

Sep 11, 2024

Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU

A Dupixent (dupilumab) confirmatory phase 3 study met the primary and key secondary endpoints for the treatment of patients with uncontrolled, biologic-naïve chronic spontaneous urticaria (CSU) receiving background therapy with antihistamines. The study showed clinically meaningful reductions in itc...

N/A

Sep 11, 2024

Login to view more news

Dive into the world of investing with Prosperse

Explore our recent articles to learn more about how Prosperse can help you achieve your financial goals.

Read more news from Prosperse